DK0915648T3 - Fremgangsmåder og præparater til selektiv modificering af nukleinsyrer - Google Patents

Fremgangsmåder og præparater til selektiv modificering af nukleinsyrer

Info

Publication number
DK0915648T3
DK0915648T3 DK96929846T DK96929846T DK0915648T3 DK 0915648 T3 DK0915648 T3 DK 0915648T3 DK 96929846 T DK96929846 T DK 96929846T DK 96929846 T DK96929846 T DK 96929846T DK 0915648 T3 DK0915648 T3 DK 0915648T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
nucleic acids
selectively modifying
modifying nucleic
Prior art date
Application number
DK96929846T
Other languages
Danish (da)
English (en)
Inventor
Edward I Budowsky
K Ackerman Samuel
Original Assignee
Vi Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vi Technologies Inc filed Critical Vi Technologies Inc
Application granted granted Critical
Publication of DK0915648T3 publication Critical patent/DK0915648T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/12—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10161—Methods of inactivation or attenuation
    • C12N2730/10163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32461—Methods of inactivation or attenuation
    • C12N2770/32463—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18161—Methods of inactivation or attenuation
    • C12N2795/18163—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Peptides Or Proteins (AREA)
DK96929846T 1995-08-29 1996-08-29 Fremgangsmåder og præparater til selektiv modificering af nukleinsyrer DK0915648T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/521,245 US6114108A (en) 1995-08-29 1995-08-29 Methods and compositions for the selective modification of viral nucleic acids
PCT/US1996/014040 WO1997007674A1 (fr) 1995-08-29 1996-08-29 Procedes et compositions de modification selective d'acides nucleiques

Publications (1)

Publication Number Publication Date
DK0915648T3 true DK0915648T3 (da) 2002-08-26

Family

ID=24075988

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96929846T DK0915648T3 (da) 1995-08-29 1996-08-29 Fremgangsmåder og præparater til selektiv modificering af nukleinsyrer

Country Status (18)

Country Link
US (1) US6114108A (fr)
EP (2) EP0915648B1 (fr)
JP (2) JP2001520635A (fr)
KR (1) KR100486765B1 (fr)
AT (2) ATE319483T1 (fr)
AU (1) AU694892B2 (fr)
BR (1) BR9610306A (fr)
CA (1) CA2230671A1 (fr)
DE (2) DE69621161T2 (fr)
DK (1) DK0915648T3 (fr)
ES (1) ES2173314T3 (fr)
HK (1) HK1042254A1 (fr)
IL (1) IL123467A0 (fr)
NO (1) NO980881L (fr)
NZ (1) NZ316787A (fr)
PL (1) PL187759B1 (fr)
PT (1) PT915648E (fr)
WO (1) WO1997007674A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691132A (en) 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
US6177441B1 (en) 1995-06-05 2001-01-23 Cerus Corporation Treating red blood cell solutions with anti-viral agents
US20040048235A1 (en) * 1995-08-29 2004-03-11 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
DE19633684A1 (de) * 1996-08-12 1998-02-19 Dirk Dipl Ing Vollenbroich Verfahren zur Inaktivierung von lipidumhüllten Viren
US6514987B1 (en) 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
US6093725A (en) * 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6352695B1 (en) * 1997-10-03 2002-03-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US7569342B2 (en) 1997-12-10 2009-08-04 Sierra Molecular Corp. Removal of molecular assay interferences
CN1203900C (zh) 1998-01-06 2005-06-01 塞鲁斯公司 用于淬灭生物材料中病原体灭活剂的方法
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
AU4435399A (en) 1998-06-11 1999-12-30 Cerus Corporation Inhibiting proliferation of arterial smooth muscle cells
DE19827750C1 (de) * 1998-06-22 1999-07-29 Centeon Pharma Gmbh Verfahren zum Abtrennen von HIV aus einer Flüssigkeit
US6908553B1 (en) 1998-07-08 2005-06-21 Baxter International Inc. Composite membrane with particulate matter substantially immobilized therein
US6099734A (en) * 1998-07-08 2000-08-08 Baxter International Inc. Apparatus, membranes and methods for removing organic compounds from a biological fluid
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
DE19836559A1 (de) 1998-08-12 2000-03-23 Antigen Gmbh Gefäß zur Entnahme von Blut
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6617100B2 (en) 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
JP2002525131A (ja) * 1998-09-25 2002-08-13 ブイ．アイ． テクノロジーズ インク． 生物学的組成物においてウイルスを選択的に不活化する方法
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
IL146126A0 (en) 1999-04-30 2002-07-25 Slil Biomedical Corp Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
AU2002243363A1 (en) * 2000-11-06 2002-07-24 V.I. Technologies, Inc. Use of aziridino-compounds in the treatment of immune dysfunctions
US6602718B1 (en) 2000-11-08 2003-08-05 Becton, Dickinson And Company Method and device for collecting and stabilizing a biological sample
US20020131958A1 (en) * 2001-01-22 2002-09-19 John Chapman Method for purifying a biological composition
US6635679B2 (en) * 2001-05-14 2003-10-21 Akzo Nobel N.V. Methods and compositions for inactivating viruses
WO2002092806A1 (fr) * 2001-05-15 2002-11-21 V.I. Technologies, Inc. Appareils permettant d'inactiver des pathogenes dans des fluides contenant des proteines
US20030130356A1 (en) 2001-10-16 2003-07-10 Slil Biomedical Corporation Oligoamine compounds and derivatives thereof for cancer therapy
JP2005517023A (ja) * 2001-11-06 2005-06-09 ヴイ．アイ．テクノロジーズ，インコーポレーテッド アジリジン化合物の治療的使用
WO2003057129A1 (fr) 2001-12-28 2003-07-17 Terumo Kabushiki Kaisha Systeme de sac sanguin et procede d'inactivation de micro-organismes pathogenes
US20050074743A1 (en) * 2003-10-06 2005-04-07 Purmal Andrei A. Method and composition for treating a biological sample
AU2005302256B2 (en) 2004-10-29 2011-01-20 Cerus Corporation Improved quenching methods for red blood cell inactivation process
CA2720824C (fr) 2008-04-09 2021-09-14 Cerus Corporation Procedes ameliores de traitement pour l'inactivation des pathogenes de globules rouges
EA034543B1 (ru) 2012-06-01 2020-02-19 Бёрингер Ингельхайм Ветмедика Гмбх Иммуногенная композиция (вакцина) против вируса шмалленберга (sbv), способ ее получения и способ индукции иммунного ответа против sbv
EP4105321A1 (fr) 2015-11-01 2022-12-21 Glycobac, LLC Lignées cellulaires exemptes de virus et procédés d'obtention de celles-ci
WO2017197034A1 (fr) 2016-05-10 2017-11-16 Najit Technologies, Inc. Oxyanions polyatomiques inorganiques pour la protection contre les dommages antigéniques pendant l'inactivation d'agents pathogènes pour la production de vaccins
KR102198877B1 (ko) 2019-07-16 2021-01-05 정소영 블루 라이트 차단 필터
CN113322252B (zh) * 2020-12-28 2026-04-03 广州凯普医药科技有限公司 一种拭子样本保存液

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492289A (en) * 1966-06-13 1970-01-27 Dow Chemical Co Polymers of alkylenimines
US4058599A (en) * 1973-02-24 1977-11-15 Bayer Aktiengesellschaft Ethyleneimine inactivated organisms
US4036952A (en) * 1973-02-24 1977-07-19 Bayer Aktiengesellschaft Ethyleneimine inactivated microorganisms
RU594771C (ru) * 1973-05-07 1993-07-07 Всесоюзный научно-исследовательский ящурный институт Средство дл инактивации вирусов при изготовлении противовирусных препаратов
US4841023A (en) * 1986-06-25 1989-06-20 New York Blood Center, Inc. Inactivation of viruses in labile protein-containing compositions using fatty acids
US5000951A (en) * 1987-03-09 1991-03-19 Diamond Scientific Company Multivalent canine distemper virus vaccine
US5055485A (en) * 1988-12-02 1991-10-08 New York Blood Center, Inc. Inactivation of viruses in cell- and protein-containing compositions using aryl diol epoxides
RU1768636C (ru) * 1989-08-16 1992-10-15 Всесоюзный научно-исследовательский ветеринарный институт птицеводства Способ получени антигена вируса болезни Гамборо
US5120649A (en) * 1990-05-15 1992-06-09 New York Blood Center, Inc. Photodynamic inactivation of viruses in blood cell-containing compositions
US5232844A (en) * 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
EP0500893A4 (en) * 1990-09-04 1993-03-10 Edward Shanbrom Preservation of blood, tissues and biological fluids
GB9108682D0 (en) * 1991-04-23 1991-06-12 Wellcome Found Production of vaccines
FR2679253B1 (fr) * 1991-07-15 1994-09-02 Pasteur Institut Proteines de resistance a la cycloheximide. utilisation comme marqueur de selection par exemple pour controler le transfert d'acides nucleiques.
EP0612532A3 (fr) * 1993-02-26 1998-02-04 Solvay Animal Health, Inc. Vaccin contre le coronavirus canin à partir de coronavirus entérique félin
EP0773716A4 (fr) * 1995-06-07 1999-08-04 Cerus Corp Traitement de solutions de globules rouges par des agents antiviraux

Also Published As

Publication number Publication date
KR100486765B1 (ko) 2005-09-02
ES2173314T3 (es) 2002-10-16
DE69635871D1 (de) 2006-05-04
WO1997007674A1 (fr) 1997-03-06
EP1129728A1 (fr) 2001-09-05
EP1129728B1 (fr) 2006-03-08
IL123467A0 (en) 1998-09-24
HK1042254A1 (en) 2002-08-09
ATE319483T1 (de) 2006-03-15
NZ316787A (en) 1999-11-29
AU6909996A (en) 1997-03-19
DE69621161T2 (de) 2002-11-21
BR9610306A (pt) 1999-07-06
CA2230671A1 (fr) 1997-03-06
EP0915648A4 (fr) 1999-05-19
PT915648E (pt) 2002-09-30
EP0915648A1 (fr) 1999-05-19
US6114108A (en) 2000-09-05
EP0915648B1 (fr) 2002-05-08
JP2001520635A (ja) 2001-10-30
JP2003176238A (ja) 2003-06-24
DE69635871T2 (de) 2007-05-24
PL187759B1 (pl) 2004-10-29
ATE217144T1 (de) 2002-05-15
KR19990044303A (ko) 1999-06-25
DE69621161D1 (de) 2002-06-13
NO980881L (no) 1998-04-27
AU694892B2 (en) 1998-07-30
PL325338A1 (en) 1998-07-20
NO980881D0 (no) 1998-02-27

Similar Documents

Publication Publication Date Title
DK0915648T3 (da) Fremgangsmåder og præparater til selektiv modificering af nukleinsyrer
ATE544466T1 (de) Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
DK0853660T3 (da) Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel
DE69637181D1 (de) Vorrichtung zur inaktivierung von viralen kontaminationen in blutprodukten
CY1105389T1 (el) Hpv-e7 ως αγωγη εναντι του ιου θηλωματων ανθρωπου
DE69329108D1 (de) Verfahren zur inaktivierung von viren
DE69533673D1 (de) Behandlung und prävention von helicobacter-infektionen
AU7814498A (en) Multivalent (in ovo) avian vaccine
ATE402713T1 (de) Genetisch manipulierte herpesviren zur behandlung von tumoren
MX9202781A (es) Vacuna y metodo de tratamiento para virus de inmunodeficiencia humana.
ATE290548T1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
WO2002096471A3 (fr) Procede d'inactivation virale utilisant un antioxydant
ATE372129T1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
EP0600396A3 (fr) Vaccins à partir de protozoaires intestinaux.
ATE283920T1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
DE10075036I2 (de) Impfstoff und Diagnostikum f}r den Schweine-Cholera-Virus.
DK0684842T3 (da) Præparat til behandling af tumorer og immunisering af organismer over for tumorer
ATE255594T1 (de) Hepatitis b inhibitoren
DE69637325D1 (de) Methode für die behandlung einer hepatitisvirusinfektion
ATE196424T1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
MX9400210A (es) Tratamiento de infecciones virales.